ClearPoint Neuro, Inc.: insider trades · United States · SEC (Form 4)

About ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. (ticker: CLPT) is a U.S.-listed company traded on the NASDAQ, focused on precision neurosurgery and targeted delivery solutions for the brain and spine. For French, Belgian, and Swiss investors, it fits the profile of a niche medtech company operating at the intersection of medical devices, cell therapy, and gene therapy enablement. The company is headquartered in Solana Beach, California, and also maintains manufacturing capabilities in Carlsbad, giving it a concentrated operational footprint on the west coast of the United States. ([clearpointneuro.com](https://www.clearpointneuro.com/about/?utm_source=openai)) ClearPoint Neuro was built around a precision navigation platform for intracranial procedures. Its core value proposition is real-time, image-guided hardware and software that allows neurosurgeons to make intraprocedural adjustments with a high degree of accuracy. That is strategically important because it gives the company a more defensible position than a commoditized medical-device supplier. ClearPoint emphasizes its technology depth, clinical utility, patent portfolio, and expanding adoption across specialized neurosurgical workflows. ([clearpointneuro.com](https://www.clearpointneuro.com/about/?utm_source=openai)) From a business-segment perspective, CLPT is not a single-product story. Its platform is used in deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and the delivery of drugs, biologics, and gene therapies to the brain. The company describes itself as a “device, cell, and gene therapy-enabling company,” which positions it more as an infrastructure provider for advanced neuroscience treatments than as a traditional instrument maker. This model can support a revenue mix that includes systems, disposables, and a growing partner ecosystem in biopharma. ([clearpointneuro.com](https://www.clearpointneuro.com/about/?utm_source=openai)) In competitive terms, ClearPoint operates in a specialized market where clinical credibility, precision, and workflow integration matter more than scale alone. Its differentiation comes from neurosurgical navigation expertise and from its ability to support cell and gene therapy programs with pharmaceutical partners. The company stated that it has more than 60 active biopharma partners and is supporting more than 25 global clinical trials, reinforcing its role as a platform enabling CNS-focused innovation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1285550/000119312526110780/clpt-ex99_1.htm?utm_source=openai)) Recent developments have included the company’s first-quarter 2026 results released on May 13, 2026, along with ongoing execution on its expanded commercial platform. ClearPoint has also highlighted the acquisition and commercialization of a neurocritical care product line from IRRAS, as well as software innovation, including FDA-cleared updates to its 2.2 software version. For investors, this points to a company that is evolving from a focused neuromodulation/navigation specialist into a broader neuroscience platform with multiple growth vectors, while still depending on clinical adoption and partner momentum. ([ir.clearpointneuro.com](https://ir.clearpointneuro.com/news-events/press-releases?utm_source=openai))